BeiGene Ltd. (ONC)
| Bid | 257.1 |
| Market Cap | 2.19B |
| Revenue (ttm) | 3.81B |
| Net Income (ttm) | -644.79M |
| EPS (ttm) | -6.11 |
| PE Ratio (ttm) | -42.43 |
| Forward PE | 41.09 |
| Analyst | Buy |
| Ask | 260.57 |
| Volume | 229,042 |
| Avg. Volume (20D) | 536,211 |
| Open | 257.17 |
| Previous Close | 259.81 |
| Day's Range | 255.59 - 261.05 |
| 52-Week Range | 141.31 - 287.88 |
| Beta | 0.49 |
About ONC
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a sel...
Analyst Forecast
According to 6 analyst ratings, the average rating for ONC stock is "Buy." The 12-month stock price forecast is $317, which is an increase of 22.29% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · businesswire.com
BeiGene to Announce First Quarter 2025 Financial Results on May 7SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will re...
2 months ago · seekingalpha.com
BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025BeiGene is a BUY due to Tevimbra's approval and Brukinsa's growing sales, leading to anticipated positive earnings in 2025. Q4 and full-year 2024 revenues surged to $1.1B and $3.8B respectively, with ...
